EMCURE PHARMA IPO SHOULD YOU INVEST OR AVOID?

Emcure Pharma IPO is a Book built issue of Rs.1952/-crore and is a combination of fresh issue and offer for sale where existing promoters are exiting the Company.

IMPORTANT DATES TO BE NOTED:

Emcure Pharma opens for Subscription on 3rd July and Closes on 7th July 2024.The allotment is expected on 8th July 2024 and Listing in NSE, BSE on 10th July 2024.

Emcure Pharma IPO Allots 29.67% to Anchor Investors,19.78% to QIB,14.83% to NII,34.61% to Retail Investors and Employees are offered 0.56% with a discount of 90/-Rs to Issue Price.

EMCURE PHARMA IPO
EMCURE PHARMA IPO

GREY MARKET PREMIUM FOR EMCURE IPO:

According to Unlisted dealers,GMP of Emcure is trading at a premium of 30%, GMP is a tool to understand the Listing price of the IPO.It varies on day-to-day basis and cannot totally relay on it.

FINANCIALS OF THE EMCURE PHARMA IPO:

Revenue and Reserves have been increasing during FY2022-24, While Profit has been decreasing.

Period Ended 31 Mar 2024 31 Mar 2023 31 Mar 2022
Assets 7,806.16 6,672.53 6,063.47
Revenue 6,715.24 6,031.72 5,918.86
Profit After Tax 527.58 561.85 702.56
Net Worth 2,952.28 2,501.13 1,987.55
Reserves and Surplus 2,722.40 2,293.77 1,791.03
Total Borrowing 2,091.94 2,202.42 2,102.19

RISK TO INVESTORS:

  • Income tax department has issued assessment orders during dec 2020.
  • Company was issued Show-Cause notice for Non-Compliance with Company Act.
  • Company has experienced negative cash and cash equivalent in FY2022, FY2023.

Leave a Comment